Trial Profile
An Open-Label, Three-Cohort, Phase 2 Study of E7080 (Lenvatinib) in Subjects With Recurrent Malignant Glioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2022
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Bevacizumab
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 20 May 2016 Status changed from discontinued to completed.
- 27 Dec 2013 Actual study completion date added as reported by ClinicalTrials.gov record.
- 26 Dec 2013 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov..